CYTH vs. VXRT, CRDF, MOLN, VIGL, LIFE, SGMO, OMGA, DBVT, ATHA, and BLUE
Should you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Vaxart (VXRT), Cardiff Oncology (CRDF), Molecular Partners (MOLN), Vigil Neuroscience (VIGL), aTyr Pharma (LIFE), Sangamo Therapeutics (SGMO), Omega Therapeutics (OMGA), DBV Technologies (DBVT), Athira Pharma (ATHA), and bluebird bio (BLUE). These companies are all part of the "biological products, except diagnostic" industry.
Vaxart (NASDAQ:VXRT) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
Vaxart has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.
Vaxart presently has a consensus target price of $3.00, suggesting a potential upside of 268.10%. Cyclo Therapeutics has a consensus target price of $3.20, suggesting a potential upside of 150.00%. Given Cyclo Therapeutics' higher possible upside, analysts clearly believe Vaxart is more favorable than Cyclo Therapeutics.
Vaxart has a net margin of -920.00% compared to Vaxart's net margin of -1,720.76%. Cyclo Therapeutics' return on equity of -121.06% beat Vaxart's return on equity.
Vaxart received 301 more outperform votes than Cyclo Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Cyclo Therapeutics an outperform vote while only 65.47% of users gave Vaxart an outperform vote.
Cyclo Therapeutics has lower revenue, but higher earnings than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks.
18.1% of Vaxart shares are owned by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are owned by institutional investors. 3.0% of Vaxart shares are owned by insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Cyclo Therapeutics had 4 more articles in the media than Vaxart. MarketBeat recorded 5 mentions for Cyclo Therapeutics and 1 mentions for Vaxart. Cyclo Therapeutics' average media sentiment score of 1.89 beat Vaxart's score of 0.57 indicating that Vaxart is being referred to more favorably in the media.
Summary
Vaxart beats Cyclo Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Cyclo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclo Therapeutics Competitors List
Related Companies and Tools
